At the moment, Galena Biopharma (NASDAQ: GALE) sharholders would suggest they have one such gold mine in NeuVax. The cancer immunotherapy vaccine is being studied in late-stage trials and is designed to act as an adjuvant therapy to prevent the reccurrence of breast cancer in patients with low-to-moderate HER2-expression. Cancer immunotherapies are garnering tons of attention right now since they work side-by-side with your immune system to give it a better shot at locating and destroying cancer cells.
\
Source: Galena Biopharma.
In phase 2 studies, cancer recurred in just 5.6% of the NeuVax intent-to-treat group after 60 months. By comparison, cancer recurred in 25.9% of the control group that wasn't given NeuVax, resulting in a statistically significant 78.4% clinical benefit. The trial results also demonstrated that NeuVax had few side effects and was well tolerated by trial participants.
If NeuVax is approved it could transform post-surgical treatment for low-to-moderate HER2-expression breast cancer patients, and it would likely make Galena profitable in short order. Based on its current market value, Galena would also turn out to be incredibly inexpensive if NeuVax is approved, which is why today's shareholders are so excited about its prospects.
